Brought to you by 
Aclaris buys Confluence Life Sciences for $20mm plus $80mm in earn-outs
22 Sep 2020
Executive Summary
Aclaris Therapeutics Inc. acquired private kinase inhibitor firm Confluence Life Sciences Inc. for $20mm up front ($10mm in cash and $10mm in Aclaris common shares). Confluence shareholders could also get up to $80mm in earn-outs for development, regulatory, and sales achievements, plus low-single-digit royalties.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aclaris buys Confluence Life Sciences for $20mm plus $80mm in earn-outs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice